Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 19, 2023

SELL
$1.93 - $3.64 $233,916 - $441,168
-121,200 Reduced 83.76%
23,500 $53,000
Q2 2023

Jul 18, 2023

BUY
$2.38 - $3.67 $344,386 - $531,049
144,700 New
144,700 $426,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $33M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Denali Advisors LLC Portfolio

Follow Denali Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Denali Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Denali Advisors LLC with notifications on news.